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ABSTRACT the enzyme-linked immunosorbent assay (eliSA) and indi-
rect immunofluorescence (iiF) have both been used for testing of anti-
bodies to desmogleins 1 and 3 (anti-Dsg1 and anti-Dsg3) and for the 
serologic diagnosis of pemphigus. iiF values and antibody concentra-
tions and profile do not always correlate with a specific clinical pheno-
type and with the disease activity. the purpose of the present study was 
to correlate the clinical phenotype of patients with pemphigus vulgaris 
(PV) and the disease activity with anti-Dsg1 and anti-Dsg3 antibodies 
and iiF titers. A total of 72 patients with PV underwent eliSA serum test-
ing for the presence and titers of anti-Dsg1 and anti-Dsg3 and iiF which 
were correlated with the severity of the disease (evaluated using the 
Pemphigus Disease Area index, PDAi), clinical phenotype, and clinical 
course. in 79.2% patients there was a perfect correlation between the 
clinical phenotype and antibody profiles; in 20.8% patients, clinical fea-
tures and antigenic findings were discordant. A statistically significant 
correlation was found between disease activity and a) anti-Dsg3 and 
anti-Dsg1 concentrations (rho=0.679, P<0.001 and rho=0.363, P=0.02, 
respectively) and b) iiF titers (rho=0.426, P<0.01), as well between iiF 
titers and anti-Dsg3 and anti-Dsg1 antibodies (rho=0.742, P<0.01 and 
rho=0.372, P=0.02, respectively).  this study supports the previous ob-
servations that the disease severity in most patients with pemphigus 
correlates with iiF titers, which in turn is determined by the quantities of 
Dsg1 and Dsg3 antibodies, as well as the previous observation that the 
clinical phenotype and antibody profile are not always in correlation.





eliSA: enzyme-linked immunosorbent assay
iiF: indirect immunofluorescence
M PV: mucosal dominant pemphigus vulgaris
MC PV: mucocutaneous pemphigus vulgaris
PDAi: Pemphigus Disease Area index
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INTRODUCTION
Pemphigus vulgaris (PV) is a rare and serious au-
toimmune blistering disease of the skin and mucous 
membranes, with autoantibodies directed against 
two major antigens on the surface of keratinocytes 
– desmoglein 1 (Dsg1) and desmoglein 3 (Dsg3) (1). 
Studies using indirect immunofluorescence (iiF) sug-
gested that antibody titers correlate with disease 
activity (2). Development of enzyme-linked immu-
nosorbent assays (eliSAs) for detection of anti-Dsg1 
and anti-Dsg3 confirmed the significance of those au-
toantibodies in the pathogenesis of pemphigus and 
demonstrated higher sensitivity and specificity than 
iiF (3-5). it is generally believed that predominantly 
oral PV is characterized by the presence of anti-Dsg3 
alone, whereas mucocutaneous PV is characterized 
by the presence of both anti-Dsgs (4-6) and that the 
alterations in the autoantibody profile in the sera of 
patients with PV correlate with the disease activity 
(7-10). 
in this study, correlations were made between an-
tibody profiles in patients with different subtypes of 
PV and between anti-Dsg1, anti-Dsg3, and iiF values 
which were also assessed in relation to disease sever-
ity and stage.
PATIENTS AND METHODS
this study was conducted as a cross-sectional 
study. From January 2012 to December 2013, seven-
ty-two patients (46 women and 26 men) aged 20-88 
years (mean age 53.5 years), with diagnosed PV based 
on clinical examination, direct immunofluorescence, 
and histopathology, were included in the study. Pa-
tients were classified into two groups (mucocutane-
ous and mucosal dominant type) based on the distri-
bution of lesions. Different stages of the disease were 
defined following the consensus statement on pem-
phigus (11) and disease severity was evaluated using 
the Pemphigus Disease Area index (PDAi) (12).
A single blood sample for autoantibodies detec-
tion was obtained from all patients (n=72). newly-
diagnosed patients were sampled at the time of ad-
mission, before starting the treatment. Patients in re-
lapse were sampled after exacerbation, and patients 
in remission at routine check-ups. Before sampling, 
written consent was obtained from each subject. this 
study is in accordance with the standards of the Hel-
sinki Declaration and has been approved by the ethi-
cal Committee of the Clinical Center of Serbia and the 
ethical Committee of the University of Belgrade.
Table 1. indirect immunofluorescence (iiF) titers, antibody profile and disease severity of patients with pem-
phigus vulgaris (PV)
Pemphigus type Dsg1-/Dsg3- Dsg1+/Dsg3- Dsg1-/Dsg3+ Dsg1+/Dsg3+ Total
MC PV (n=64) 5 (7.8%) 7 (10.9%) 20 (31.2%) 32 (50.0%) 64 (100%)
Negative IIF 3 3 3 3 12 (18.75%)
IIF: 1/20, 1/40 2 3 7 8 20 (31.25%) 
IIF: 1/80 0 1 2 9 12 (18.75%)
IIF: ≥1/160 0 0 8 12 20 (31.25%)
PDAI, median (IQR) 9 (1.5-24.0) 32 (11-36) 10.5 (1.75-46.0) 53.5 (37.5-65.7)†,‡ 38 (11.25-54.0)
M PV (n=8) 3 (37.5%) 0 5 (62.5%) 0 8 (100.0%)
Negative IIF 2 0 2 0 4 (50.0%)
IIF: 1/20, 1/40 1 0 0 0 1 (12.5%)
IIF: 1/80 0 0 2 0 2 (25.0%)
IIF: ≥1/160 0 0 1 0 1 (12.5%)
PDAI, median (IQR) 3 0 21 (8-26.5) 0 10 (4-23.25)
*iQr: interquartile range; MC PV: mucocutaneous pemphigus vulgaris; M PV: mucosal dominant pemphigus vulgaris; PDAi: 
Pemphigus Disease Area index 
PDAi was significantly higher in MC PV patients with a Dsg1+/Dsg3+ profile (bold) compared with MC PV patients with a 
†Dsg1-/Dsg3+ (p<0.001) or with ‡Dsg1+/Dsg3- profile (P=0.016). 
iiF titers were significantly higher in MC PV patients with a Dsg1+/Dsg3+ profile compared with MC PV patients with †Dsg1-
/Dsg3+ (P=0.029)
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Indirect immunofluorescent tests and 
autoantibody determination
Serum specimens for iiF were serially diluted with 
phosphate-buffered saline and incubated on monkey 
esophagus as the epithelial substrate. iiF titers were 
classified into four groups, 1) negative, 2) positive, ti-
ters at 1 ⁄ 20 and 1/40, 3) positive, titer at 1/80, and 4) 
positive at 1⁄160 or higher dilution.
eliSA was performed using commercially avail-
able Dsg1 and Dsg3 eliSA tests (eUrOiMMUn Med-
izinische labordiagnostikaAG, lübeck, Germany) 
according to the manufacturer’s instructions. All 
sera were initially diluted 100-fold; if necessary, sera 
were diluted at 1:400 as instructed by manufacturer 
to obtain an index value (iV) under 200 rU/ml. true 
iVs were obtained by multiplying the original iVs with 
the dilution factor (×4). An eliSA index value >20.0 
was considered positive for both anti-Dsg1 and anti-
Dsg3. 
Obtained Dsg iV and iiF values were correlated 
with disease activity expressed as a PDAi score.
Statistical analysis
Data are presented as number (percent) and or 
median (along with 1st-3rd quartile), depending on 
data distribution. the Kruskal-Wallis test and Mann-
Whitney U-test were used to compare groups. Spear-
man correlation analysis was used to analyze correla-
tion between variables. P values were corrected for 
multiple comparisons according to the Bonferroni 
method. All data were analyzed using SPSS 20.0 (iBM 
corp.). All P values lower than 0.05 were considered 
significant.
RESULTS
Disease severity, antibody profile, and  
IIF titers
the disease severity (PDAi), presented as the 
median value with interquartile range (iQr), was 
stratified in table 1 according anti Dsg profile and iiF 
values. 
there was a correlation between the clinical phe-
notype and antibody profiles in 79.2% of patients 
(52/64 with MC PV and 5/8 with M PV); in 20.8% pa-
tients the clinical phenotype and the antigenic pro-
file were discordant (table 1).
the iiF test was positive in 56/72 (77.8%) patients 
and negative in 16/72 (22.2%) patients (12 with MC 
PV, 4 with M PV) (table 1). Of 8 patients with negative 
anti-Dsg antibodies 5 had a negative iiF test as well; 
the other 3 had lower iiF values (1/20 or 1/40). the iiF 
test was negative in 9 MC PV cases with either posi-
tive anti-Dsg3 or anti-Dsg1 or with an anti-Dsg3+/
anti-Dsg1+ profile, as well in two M PV patients with 
positive anti-Dsg3 antibodies (table 1).
Concentrations of anti-Dsg antibodies,  
IIF titers, and disease severity
A significant correlation was found between 
the severity of PV (PDAi) and iiF titers (rho=0.426, 
p<0.001) and between iiF titers and anti-Dsg3 and 
anti-Dsg1 antibodies (rho=0.742, p<0.001 and 
rho=0.372, p=0.02, respectively) (table 2). 
Concordance was observed between iiF and anti-
Dsg3 values since the kappa coefficient was high 
(κ=0.469) but not between iiF and anti-Dsg1 values 
(κ=0.178) (data not shown). 
A significant correlation was detected between 
PDAi and levels of both anti-Dsg1 and anti-Dsg3 anti-
bodies (rho=0.679; p<0.001 and rho=0.363; p=0.020, 
respectively) (table 2). 
in patients with MC PV, PDAi was significantly 
higher in those with an anti-Dsg1+/anti-Dsg3+ pro-
file compared with those with anti-Dsg1-/anti-Dsg3+ 
or with anti-Dsg1+/anti-Dsg3- profiles (p<0.001 and 
p=0.016, respectively, data not shown). iiF titers were 
significantly higher in MC PV patients with an anti-
Dsg1+/anti-Dsg3+ profile compared with those with 
anti-Dsg1-/anti-Dsg3+ (p=0.029, data not shown).
Concentrations of anti-Dsg1 and anti-
Dsg3 antibodies in different stages of PV
Concentrations of anti-Dsg1 and anti-Dsg3 anti-
Table 2. Correlation of disease severity (PDAi), anti-desmoglein (Dsg) antibody concentration, and indirect 
immunofluorescence (iiF) values
PDAI Correlation Coefficient P IIF Correlation Coefficient P
Anti-Dsg3 0.363* 0.020 0.742** p<0.001
Anti-Dsg1 0.679** p<0.001 0.372* 0.020
IIF values 0.426** p<0.001
** Correlation is significant at the 0.01 level  
* Correlation is significant at the 0.05 level  
PDAi: Pemphigus Disease Area index
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bodies and iiF values in patients in various stages of 
the disease are summarized in table 3. 
the statistical significance of differences in anti-
Dsg1 titers was calculated comparing new patients 
and 1) patients in relapse, 2) patients in complete re-
mission, on and off therapy, as there was statisticaly 
significant difference in  anti-Dsg3 titers between pa-
tients in complete remission on therapy and 1) new 
patients and 2) patients in relapse. After correction, 
P values showed a statistically significant difference 
only between anti-Dsg1 levels in new patients and a) 
patients in complete remission on and b) off therapy 
(P adj= 0.01 and P adj= 0.011, respectively). 
the statistical significance of iiF values was calcu-
lated comparing patients in complete remission on 
therapy and 1) patients in disease relapse and 2) new 
patients. Corrected P values showed a statistically 
significant difference only between new patients and 
patients in complete remission on therapy (P=0.016).
the statisticaly significant difference in iiF titers 
and anti-Dsg3 levels between MC and M PV in new 
patients and patients in relapse was not recorded due 
to the small sample of M PV patients.
in all patients in complete remission and off ther-
apy (n=7), anti-Dsg1 antibodies were negative, while 
anti-Dsg3 antibodies were detectable in 6/7 patients 
although they were disease-free and without any 
treatment ≥6 months; iiF titers were detectable or in 
a high titer in 5/7 patients (table 4). in 9/13 patients in 
complete remission on therapy, anti-Dsg1 antibodies 
were negative; anti-Dsg3 antibodies were negative in 
8/13 and detectable in 5/13 patients, with iiF values 
either negative or positive at lower dilutions, with the 
exception of two patients with highly positive anti-
Dsg3 antibodies (table 4).  
DISCUSSION
For many years, iiF has been the standard test for 
detection of pemphigus autoantibodies and is still 
the standard assay to detect the intercellular antibod-
ies associated with pemphigus (13). in patients with 
PV, iiF sensitivity has been reported at 70% to 90%, 
depending partially on the substrate used (2,13). to 
increase iiF sensitivity, a combination of substrates is 
used; with this modification iiF could still be used as an 
alternative test especially when eliSA is not available 
(2). eliSA is regarded as a specific tool for the diagno-
sis of pemphigus (14). Positive correlation between iiF 
titers and eliSA values has been recorded (6). 
We found positive iiF tests in 77.8% patients; among 
16 patients with negative iiF, 5 had negative anti-Dsg3 
and anti-Dsg1 antibodies, 3 had negative anti-Dsg3 
antibodies, and the other 8 patients had positive anti-
Dsg antibodies (anti-Dsg3 or anti-Dsg1 or both) which 
could suggest eliSA as a useful diagnostic tool in pa-
tients with PV that have negative iiF.  the significance 
of both assays is indicated by the recorded correlation 
of eliSA and iiF with the disease activity as well as the 
high correlation rate between iiF values and anti-Dsg3 
(κ=0.469). this correlation rate was not observed be-
tween anti-Dsg1 values and iiF titers.
Table 3. Values of anti desmoglein (Dsg) 1 and 3 antibodies levels and total Pemphigus Disease Area index 
(PDAi) in patients with pemphigus vulgaris (PV) in various stages of the disease
Stage of disease and PV 
subtype
Dsg1 (RU/mL)* Dsg3 (RU/mL)* IIF* PDAI*
New patients (n=40)
(M=4, MC=36)




3.0 (1.25-157.78) 155.25 (122.13-249.53) 1/80 (0-1/640) 26.50 (18.75-45.25)
Complete remission, on 
therapy (n=13)
(M=1, MC=12)
2.45 (0.67-22.80)a 21.70 (2.15-203.73) 1/20 (0- 1/320)c 8.50 (3.75-11.25)
Complete remission, off 
therapy (n=7)
(M=1, MC=6)
2.50 (0.83-5.90) b 152.15 (33.43-800.0) 1/80 (0- 1/640) 0.50 (0.00-1.00)
Total (n=72) 26.65 (2.03-163.33) 153.60 (30.63-254.05) 1/40 (0-1/1280) 32.50 (10.25-53.75)
M: mucosal dominant type PV, MC: mucocutaneous PV 
*Median (interquartile range) 
†compared with patients in complete remission, on therapy 
‡compared with patients in complete remission, off therapy 
After Bonferroni correction, statistical significance was recorded in anti Dsg1 levels values in patients during complete 
remission, on therapy, compared with new patients with PV (P adj=a0.01 and b0.011), and for iiF titers in patients during 
complete remission, on therapy, compared with new patients (P adj=c0.016) with PV. 
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Several studies have shown that antibody speci-
ficities and titer do not always correlate to the clini-
cal phenotype (7,9,15). in the majority of our patients 
(79.2%), the antibody profile was in correlation with 
the clinical phenotype, whereas this was not the 
case in the other 20.8% patients. in seven (10.9%) 
patients with MCP, only anti-Dsg1 antibodies were 
present (with iiF titers ranging from negative up to 
1/80 in one patient). Contrary to Mortazavi et al., who 
reported an antibody profile compatible with PF in 
one patient with the clinicopathological setting of 
PV and suggested that the anti-Dsg3 autoantibody 
level might be too low to cause mucosal lesions (16), 
all our patients with only anti-Dsg1 antibodies had 
mucosal lesions. the iiF test was 1/80 in one patient 
and ranged from negative to 1/40 in other anti-Dsg3 
negative patients. the clinicopathological settings of 
our Dsg1+/Dsg3- MC PV patients were not consistent 
with PF. the patients received further follow-up due 
to a possible shift to PF. 
it has been suggested that the presence of anti-
Dsg1 antibodies predicts a potentially more severe 
disease subgroup (7). Our observations are similar. 
A statistically significance difference was recorded 
between the disease severity of patients with MC PV 
who were Dsg1+/Dsg3- vs. Dsg1+/Dsg3+.
We recorded 5/64 (7.8%) MC PV patients who were 
Dsg3-/Dsg1-; iiF test was negative in three of them. 
they were in complete remission while on therapy. 
Although it could be argued that immunosuppres-
sive therapy may influence the antigenic profiles, this 
is presently unknown (17,18). 
All our patients with M PV were anti-Dsg1 nega-
tive. in other studies, anti-Dsg1 autoantibodies were 
recorded in various percentages in patients with M 
PV (6,7,17,19). Mucosal-limited PV may rarely lack 
anti-Dsg3 (6,20). in our study, 3/8 patients with M 
PV were anti-Dsg3 negative (one new patient, with a 
low iiF titer of 1/20, the other two patients being in 
complete remission on or off therapy, with negative 
iiF). We can only speculate that our results (both in 
patients with MC and M PV) could be similar to other 
reports where negative eliSA values were explained 
by the presence of pathogenic antibodies to non-
desmoglein molecules or to the intracellular domain 
of Dsg1/Dsg3, undetectable by eliSA (4,20,21). Alter-
natively, following Avgerinou et al. who attributed 
their findings to a possibly particular feature of PV in 
that geographic area (6), we could make a similar at-
tribution. 
We found anti-Dsg3+ and anti-Dsg1+ in a lower 
percentage than other reports, 81.2% and 60.9% of 
patients with MC PV, respectively (6,16,17).
interestingly, anti-Dsg1 antibodies were negative 
in 7/12 patients with MC PV in disease relapse (two of 
the patients had negative iiF, while the other five had 
iiF titers ranging from 1/20-1/80). in the other three 
patients with MC PV with disease relapse that were 
anti-Dsg1 negative, iiF titer was 1/80.
Table 4. Anti-desmoglein (Dsg) 1 antibodies, anti-Dsg3 antibodies, and indirect immunofluorescence (iiF) 

























N1 MC 0.5 1.5 1/20 CS, A N 1 MC 27 8.3 780.0 1/640
N2 MC 162.2 3.7 1/20 CS, A N 2 MC 48 5.1 780.0 1/80
N3 MC 21.8 28.1 1/40 CS N3 MC 6 7.7 800.0 1/320
N4 MC 25.8 2.0 0 CP N4 MC 88 1.5 91.3 1/20
N5 MC 0.6 4.3 0 CP N5 MC 102 3.5 213.0 1/80
N6 MC 7.5 233.8 1/40 CS, A N6 MC 6 7.7 780.0 1/80
N7 MC 0.9 2.0 0 CS, A N7 M 8 0.3 3.8 0
N8 MC 1.8 150.0 1/20 CS, A
N9 MC 85.5 62.4 1/40 A
N10 MC 3.5 213.0 1/80 CS
N11 MC 2 287.2 1/320 CS
N12 MC 2.9 193.7 1/20 CP
N13 M 0.7 15.3 0 CS
M: mucosal dominant; MC: mucocutaneous; CS: corticosteroids (prednisone equivalent of 10-30 mg daily); A: Azathioprine 
(25-50 mg daily); CP: Cyclophosphamide (50 mg daily)
Živanović et al. Acta Dermatovenerol Croat
Antibodies to desmogleins in patients with pemphigus   2017;25(1):8-14
13
Unexpectedly, there was no statistically signifi-
cant difference between anti-Dsg3 levels in patients 
in various stages of PV nor between patients with ac-
tive disease and either MC or M PV. We might explain 
the former by the presence of extremely high anti-
Dsg3 levels in the majority of patients in complete re-
mission, while the latter is probably due to the small 
number of patients with M PV in various stages of 
disease.
We conclude that, despite a rough correlation be-
tween antibody profile and clinical phenotype, the 
former cannot be regarded as an absolute marker 
for predicting the latter. this is in accord with other 
reports (6,7,9). in several studies, disappearance of 
Dsg3 antibodies was steadier and delayed compared 
with anti-Dsg1 antibodies (7,16,18,21,22). Our obser-
vations were similar to previously published data. 
Major study limitations included a lack of initial 
eliSA evaluation and iiF testing and serial sampling in 
various stages of the disease in all patients. A detailed 
prospective study for evaluating the eliSA levels of a 
given patient for prolonged periods would be helpful 
in determining actual correlation with disease sever-
ity and changes that may occur in the spectrum of 
the disease. 
CONCLUSIONS
Our findings suggest that  the clinical phenotype 
is related to the antibody profile in the majority of 
patients, with a discordant clinical phenotype and 
antibody profile in occasional cases. the antibody 
concentrations and iiF titers correlate with disease 
severity in most cases. Anti-Dsg3 antibodies and iiF 
values are reduced upon treatment but may persist 
in higher concentrations for long periods in patients 
in complete clinical remission. 
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